Download PDF
Market: Hong Kong Ticker: 690 ISIN: KYG9198H1406 Industry: Healthcare
Uni-Bio Science Group Ltd is a leading Chinese biopharmaceutical healthcare company engaged in the research, development, production and commercialisation of biopharmaceuticals for the Chinese healthcare market.  The Company is focused on addressing high unmet medical needs via the development and commercialisation of highly innovative therapies.

Led by a highly experienced management team and Board of Directors with broad international pharmaceutical and commercial experience, Uni-Bio Science Group Ltd was founded in 2001 and is listed on the Hong Kong Stock Exchange (Stock Code: 0690).

Uni-Bio Science Group Ltd has developed unparalleled expertise in the research, development and manufacturing of pharmaceuticals to world-class standards. The Group leverages its broad commercial presence in China for its proprietary portfolio of marketed pharmaceutical products and the products of its partners.

Key Products
Uni-Bio is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions.

Uni-Bio has a growing pipeline of novel treatments and marketed products which demonstrate strong therapeutic advantages for patients in the disease areas most in need of new solutions to growing healthcare problems – diabetes, ophthalmology and dermatology. 

 Marketed products

 Lead clinical development programs

  • GeneTime® - Dermatology
  • GeneSoft® - Ophthalmology
  • Pinpu® - Fungal infections
  • Mitiglinide – Type-2 diabetes
  • Uni-E4 – Type-2 diabetes
  • Uni-PTH - Osteoporosis and ostealgia

Expansion Strategy
China’s well-documented ageing population and growing population places great strain on our healthcare systems, however Uni-Bio has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function. 
Uni-Bio is focused on delivering against its strategic priorities to achieve sustainable growth for the Group:
Uni-Bio’s ultimate goal is to build a leading, sustainable organization that builds and delivers shareholder value by efficiently executing a number of growth strategies.

Share Data 15/10/2018
Currency HKD Volume 260,000
Previous Close 0.099 Number of Shares 6,164,968,147
Change (%) 4.21 Market Cap (mil) 610.33
Key Figures (HK$’000) 12M 2015 12M 2016 12M 2017
For the year ended 31 December
Revenue 123,364 146,489 156,477
Gross profit 102,756 123,864 133,628
EBITDA (24,653) (24,659) (45,396)
(Loss)/Profit for the year/period (59,799) (55,727) (279,309)
As at 31 December
Total assets 556,956 497,321 390,189
Total liabilities (50,296) (50,917) (47,036)
Total equity 506,660 446,404 343,153
Total fixed assets 124,777 103,328 60,257
Earnings Per Share (HK cents)
Basic (1.20)
(1.09)
(5.15)
Diluted (1.20)
(1.09)
(5.15)
Financial Indicators
Gross profit margin (%) 83.3 84.6 85.4
Current ratio (times) 3.3 2.7 4.5
Total liabilities to total asset ratio (%) 9.0 10.2 12.1
Debt to equity ratio(1) (%) 9.9 11.4 13.7
Notes:
(1) Ratio equals to total liabilities/total equity.

Share Data 15/10/2018
Currency HKD
Previous Close 0.099
Change (%) 4.21
Volume 260,000
Number of Shares 6,164,968,147
Market Cap (mil) 610.33

Key Figures (HK$’000) 12M 2015 12M 2016 12M 2017
For the year ended 31 December
Revenue 123,364 146,489 156,477
Gross profit 102,756 123,864 133,628
EBITDA (24,653) (24,659) (45,396)
(Loss)/Profit for the year/period (59,799) (55,727) (279,309)
As at 31 December
Total assets 556,956 497,321 390,189
Total liabilities (50,296) (50,917) (47,036)
Total equity 506,660 446,404 343,153
Total fixed assets 124,777 103,328 60,257
Earnings Per Share (HK cents)
Basic (1.20)
(1.09)
(5.15)
Diluted (1.20)
(1.09)
(5.15)
Financial Indicators
Gross profit margin (%) 83.3 84.6 85.4
Current ratio (times) 3.3 2.7 4.5
Total liabilities to total asset ratio (%) 9.0 10.2 12.1
Debt to equity ratio(1) (%) 9.9 11.4 13.7
Notes:
(1) Ratio equals to total liabilities/total equity.